Nice. Another $3m of contracts signed in the last two months. FY2016 revenue doubled from $10m to $20m in the last six months. I've previously had 50c as a price target based on $25m revenue, looks like that could be exceeded by clinical trials and push up around $30m if Precision and other revenue can flow in.
Still undervalued despite the strong run over the last couple of months.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.005(0.28%) |
Mkt cap ! $308.1M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.82 | $1.78 | $55.50K | 30.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2143 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 164 | 1 |
View Market Depth
| Last trade - 11.14am 23/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |